Maximum quantity allowed is 999
请选择数量
CAS RN: 61413-54-5 | 產品號碼: R0110
產品號碼 | R0110 |
純度/分析方法 | >98.0%(HPLC) |
分子式 / 分子量 | C__1__6H__2__1NO__3 = 275.35 |
外觀與形狀(20°C) | Solid |
儲存條件 | Frozen (-20°C) |
應避免的情況 | Heat Sensitive |
包裝和容器 | 250MG-Glass Bottle with Plastic Insert (閲覽圖片), 50MG-Glass Bottle with Plastic Insert (閲覽圖片) |
CAS RN | 61413-54-5 |
Reaxys-RN | 1588548 |
PubChem Substance ID | 253659657 |
Merck Index(14) | 8251 |
MDL編號 | MFCD00270906 |
產品規格
Appearance | White to Orange to Green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Melting point | 130.0 to 134.0 °C |
性質
熔點 | 132 °C |
GHS
相關法規
RTECS # | UY5749237 |
運輸資料
HS編碼* | 2933.79-000 |
Application
Rolipram: A Selective PDE4 Inhibitor
Rolipram is a selective inhibitor of phosphodiesterases 4 (PDE4s) originally developed as an antidepressant agent in 1990s, but fell out of favor because of its undesirable gastrointestinal side effects. Nowadays, rolipram continues to be used in research as a PDE4 inhibitor. PDE4s are responsible for hydrolysis of the cyclic nucleotides cAMP [A2381] and cGMP to 5’-AMP [A0158] and 5’-GMP [G0338], particularly in nerve and immune cells. The inhibition of PDE4s by rolipram induces the elevation of intracellular cAMP concentration. Consequences rolipram-induced elevation of cAMP suppress expression of proinflammatory cytokines and other mediators of inflammation. Rolipram has been reported as a drug for the treatment of autoimmune diseases, Alzheimer's disease, cognitive enhancement, and respiratory diseases like asthma and COPD. Rolipram is a racemic compound, and (R)-rolipram [R0182] is more potent than (S)-rolipram [R0183] as a PDE4 inhibitor. (The product is for research purpose only.)
References
- The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis
- Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory
- The antidepressant and antiinflammatory effects of rolipram in the central nervous system (a review)
- Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats
- Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
- Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease (a review)
考研文獻
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助,請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注:該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉,您搜索的分析圖譜無法提供。